DataMEDS AI, Inc. does not have a meaningful set of Wall Street price targets. Screening services show no individual analyst price targets with attributed firms and dates; the only listed rating is a quantitative "sell" signal, with no numeric target. Because there is no analyst consensus to average, the $4 level used here comes from public discussion and observable price action rather than published research.
Specifically, $4 is a round-number psychological level that the stock actually tested in early October 2026, closing at about $4.06 on October 1 with an intraday high near $4.35 before fading. It is therefore a defensible, publicly identifiable resistance area and milestone, not an invented or headline-driven figure. Investors should treat it strictly as a technical reference point, not as an official forecast.
Shares of DataMEDS AI closed near $2.96 on October 9, 2026, giving the company a market capitalization of roughly $8 million to $9 million. Moving to $4 would require about 35% appreciation, which for a stock of this size and volatility qualifies as a substantial move. The path is complicated by the stock's recent history: it collapsed from a 52-week high near $73.00 (set in late 2025 under the prior Wellgistics name), bottomed near $0.82 in late August 2026, then briefly spiked to an intraday high of about $12.31 in mid-September before settling back to the low-single digits.
Fundamentally, the business remains unprofitable. Reported earnings per share (EPS) are deeply negative on a trailing basis, EBITDA (earnings before interest, taxes, depreciation, and amortization) is negative, and the balance sheet is strained, with a quick ratio near 0.09 and a current ratio near 0.14. A move toward $4 would likely depend less on near-term profitability and more on continued revenue momentum, financing, and sentiment.
The chart is defined by two extremes: a 52-week low near $0.82 and a 52-week high near $73.00. More relevant near-term, the $4.00 to $4.35 zone acted as resistance in early October 2026, marking a natural hurdle on any move toward the objective. Below the current price, the mid-$2.80 to $3.00 area has provided intermittent support, while the deeper base lies in the $0.82 to $0.90 range. The wide gap between these levels reflects a broken long-term uptrend and a stock now trading in a low-priced, high-volatility regime rather than an established trend.
Unlike conventional analyst targets, which typically reflect a roughly 12-month research horizon, the $4 reference point has no attached time frame. Investors should monitor quarterly earnings and any guidance, the pace of Corexa Pharmacy revenue growth, announcements of new financing or dilution, and any Nasdaq compliance updates. Regulatory developments in telehealth and GLP-1 services, along with shifts in speculative retail sentiment, are also likely to move the stock. Because the company recently reported results in August 2026, upcoming quarterly disclosures are a key checkpoint.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like MEDS, such tools can help traders screen for opportunity, track positions, and spot shifting trends more efficiently than manual review. Traders interested in a systematic way to monitor signals across the market can explore the platform for themselves.
The question of whether DataMEDS AI can reach $4 rests on a technical milestone rather than any analyst consensus, since the company has no credible published price-target coverage. At a recent price near $2.96, the move would require roughly 35% appreciation—substantial, yet the stock traded at or above $4 only days earlier, underscoring how quickly this micro-cap can move in either direction. Supporting the case are rising pharmacy revenue and an AI and telehealth narrative, while the primary obstacles are a Nasdaq listing deficiency, persistent losses, weak liquidity, and extreme speculative volatility. Investors should weigh these forces carefully and monitor earnings, financing, and compliance developments before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that MEDS and HKPD have been poorly correlated (+7% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEDS and HKPD's prices will move in lockstep.
| Ticker / NAME | Correlation To MEDS | 1D Price Change % | ||
|---|---|---|---|---|
| MEDS | 100% | -4.69% | ||
| HKPD - MEDS | 7% Poorly correlated | -6.15% |
| Ticker / NAME | Correlation To MEDS | 1D Price Change % |
|---|---|---|
| MEDS | 100% | -4.69% |
| Distribution Services category (59 stocks) | 4% Poorly correlated | +0.75% |
| Medical Distributors category (11 stocks) | 2% Poorly correlated | +0.78% |